Apollo Hospitals Enterprise Ltd - Results for Q3 FY 2012-13 - Q.E. DEC,2012 -

Apollo Hospitals Enterprise Ltd

Dr.Pratap. C.Reddy, Chairman

Dr.Preetha Reddy, MD

Results for Q3 FY 2012-13

Q.E. DEC,2012

Stand Alone Results

Apollo Hospitals Enterprise Ltd has declared its results for the third quarter ended Dec, 2012. 

Net Sales for Q3 FY 13 stands at Rs.855.79 Cr; compared to Rs.836.32 Cr in  Q2 FY 13 (+ 2.33%); and Rs.714.75 Cr In Q3 FY 12 (+19.73%).

Total Expenditure for Q3 FY 13 stands at Rs.736.94 Cr; compared to Rs.719.32 Cr in  Q2 FY 13 (+2.45%); and Rs.620.63 Cr In Q3 FY 12 (+18.74%).

Profit before Interest, Dep. & Taxes for Q3 FY 13 stands at Rs.118.85 Cr; compared to Rs.117.00 Cr in  Q2 FY 13 (+1.58%); and Rs.94.12 Cr In Q3 FY 12 (+26.27%).

Cost of materials  for Q3 FY 13 stands at Rs.260.62 Cr; compared to Rs.213.38 Cr in  Q2 FY 13 (+22.14%); and Rs.186.93 Cr In Q3 FY 12 (+39.42%).

Purchases of S-I-T        for Q3 FY 13 stands at Rs.222.23 Cr; compared to Rs.225.50 Cr in  Q2 FY 13 (-1.45%); and Rs.185.49 Cr In Q3 FY 12 (+19.81%).

Employee benefits for Q3 FY 13 stands at Rs.135.75 Cr; compared to Rs.130.49 Cr in  Q2 FY 13 (+4.03%); and Rs.108.60 Cr In Q3 FY 12 (+25%).

Depreciation expense for Q3 FY 13 stands at Rs.27.55  Cr; compared to Rs.26.99 Cr in  Q2 FY 13 (+2.07%); and Rs.24.25 Cr In Q3 FY 12 (+13.61%).

Other expenses for Q3 FY 13 stands at Rs.131.03 Cr; compared to Rs.126.60 Cr in  Q2 FY 13 (+3.5%); and Rs.114.56 Cr In Q3 FY 12 (+14.38%).

Total expenses for Q3 FY 13 stands at Rs.736.94 Cr; compared to Rs.719.32 Cr in  Q2 FY 13 (+2.45%); and Rs.  620.63   Cr In Q3 FY 12 (+18.74%).

Profit before tax for Q3 FY 13 stands at Rs.107.56 Cr; compared to Rs.112.53 Cr in  Q2 FY 13 (-4.42%); and Rs. 91.83 Cr In Q3 FY 12 (+17.13%).

Tax Expenses  for Q3 FY 13 stands at Rs.26.92   Cr; compared to Rs.29.29 Cr in  Q2 FY 13 (-8.09%); and Rs.27.18 Cr In Q3 FY 12 (-0.96%).

Net Profit  for Q3 FY 13 stands at Rs.80.64Cr; compared to Rs.83.24 Cr in  Q2 FY 13 (-3.12%); and Rs.64.65 Cr In Q3 FY 12 (+24.73%).The YoY Growth in respect of net Sales and net Profit is  impressive.

Face Value for Q3 FY 13 stands at Rs.5 and the Paid-up Equity stands at Rs.69.56 Cr.

              

Basic EPS  for Q3 FY 13 stands at Rs.5.8; compared to Rs.6.02 in Q2 FY 13; and Rs.4.89 in Q3 FY 12

              

Public holding in the company is 61.93%.

EXCERPTS FROM THE COMPANY’S RELEASE

Apollo Hospitals announced Q3 FY13 results Strong Quarter with Well-rounded Performance. World’s #1Transplant Hospital Group with more than 1200 solid organ transplants for the year 2012, Apollo Specialty Hospital, Chennai successfully completed 500 Bone Marrow Transplants; Announces Establishment of the first Proton Therapy center for Cancer treatment in Chennai 

consolidated financial results for the quarter and nine months ended December 31, 2012.

Q3 FY13 Consolidated  Revenues up 22.2 % at Rs.9,809 million 

Consolidated EBITDA up 18.9% at Rs.1,587 million

Consolidated PAT up 22.2% at Rs.746 million 

Q3 FY13 Standalone Revenues up 19.7% at Rs.8,558  million 

Standalone EBITDA up 20.5% at Rs.1,464 million

Standalone PAT up 24.7 % at Rs.806 million

Commenting on the performance, Dr. Prathap C Reddy, Chairman said, “We are pleased to report continued growth and operating improvements in Q3 driven by sustained focus on clinical excellence. We continue to pioneer the introduction of technology based treatment in India with our plan to set up the first ever Proton Therapy Center in the region at Chennai. This new facility will offer patients across Asia, Africa and Australia the most advanced radiation therapy technology and enhance Apollo Hospitals’ ability to provide superior cancer treatment.

He added , “The improving performance of our pharmacies business is contributing to balanced growth. The sale of our stake in Apollo Health Street has also strengthened our balance sheet as we are embarking on a never before expansion plan with 14 hospitals scheduled to be added to our network over the next 30 months .”

Financial Highlights

• Standalone Q3FY13 Performance

O Revenues grew 19.7% to Rs.8,558 million compared to Rs.7,148million in Q3 FY12.

O EBITDA grew 20.5% to Rs.1,464 million as against Rs.1,215 million in Q3 FY12.

O PAT was Rs.806 million vs. Rs.647 million in Q3 FY12, growth of 24.7%.

O Diluted EPS of Rs.5.80 per share in Q3 FY13 (not annualised)

• Standalone 9M FY13 Performance

O Revenues grew 20.1 % to Rs.24,695 million compared to Rs.20,555 million in 9M FY12.

O EBITDA grew 22.2 % to Rs. 4,208 million as against Rs.3,444 million in 9M FY12.

O PAT was Rs.2,336 million in 9M FY13 vs. Rs.1,717 million in 9M FY12.

O Diluted EPS of Rs. 16.79 per share in 9M FY13 

• Consolidated Q3 FY13 Performance*#

O Revenues grew 22.2% to Rs.9,809 million compared to Rs.8,029 million in Q3 FY12.

O EBITDA grew 18.9 % to Rs.1,587 million as against Rs.1,335 million in Q3 FY12.

O PAT was Rs.746 million vs. Rs.610 million in Q 3 FY12, growth of 22.2%.

O Diluted EPS of Rs.5.36 per share in Q3 FY13 (not annualised)

• Consolidated 9M FY13 Performance*#

O Revenues grew 22.2% to Rs.28,242 million compared to Rs.23,111 million in 9M FY12.

O EBITDA grew 22.8% to Rs.4,687 million as against Rs.3,815 million in 9M FY12.

O PAT was Rs.2,351 million in 9M FY13 vs. Rs.1,741 million in 9M FY12.

O Diluted EPS of Rs.16.90 per share in 9M FY13

* The Consolidated financials are unaudited management estimates

# Apollo Health Street financials have not been considered in the consolidated financials after the Share Purchase agreement for the divestiture has been signed with Sutherland.

Operating Highlights

• Standalone Pharmacies continued to report stellar growth –Q 3 revenues grew 29.3% on a y-on-y basis to Rs.2,905 million – aided by robust same store sales growth, focus on private labels and renewed momentum in expansion of the pan - India network of stores.

• Apollo Hospitals has signed a definitive agreement with Sutherland Global Services (SGS) under which SGS will acquire a 100% stake in Apollo Health Street(AHS). The listed entity, AHEL, holds a 39% stake in AHS; the balance being held by promoters, Institutional Investors & Minority Shareholders. The deal is expected to close in Feb 2013 subject to regulatory and other conditions.

• Apollo Hospitals has announced plans to establish a Proton Therapy Center in Chennai. The center, with an approximate investment of Rs. 400 crores, is designed with state – of -the-art technology, Proteus®PLUS from IBA (Ion Beam Applications S.A.) to provide best -in-class treatment for cancer treatment.

Awards & Achievements

• Apollo Hospitals was voted the No. 1 private hospital in India (Week–HANSA Best Hospital Survey, 2012).

• Apollo Hospitals bagged the ‘Asia Responsible Entrepreneurship Awards’ (AREA) South Asia 2012 under two categories organized by Enterprise Asia on 13th December in New Delhi. Group Chairman, Dr. Prathap Reddy won the prestigious Responsible Business Leader Category and Billion Hearts Beating Foundation won the praiseworthy  Health Promotion Award.

• Indraprastha Apollo Hospitals won the “Times Research Media Healthcare Excellence Awards 2012” on 26th December 2012, in three categories - India's most innovative hospital, best diagnostic and imaging centre in North India and best heart care centre in North India.

About Apollo Hospitals Enterprise Ltd. (AHEL)

It was in 1983, that Dr. Prathap Reddy made a pioneering endeavour by launching India’s first corporate hospital - Apollo Hospital in Chennai. Now, as Asia largest and most trusted healthcare group, its presence includes over 8,020 Beds across 49 Hospitals, 1,445 Pharmacies, 100 primary care and diagnostic Clinics, 100 Telemedicine units across 10 countries (added Burma in Q3).

Health Insurance services, Global Projects Consultancy, 15 colleges of Nursing and Hospital Management and a Research Foundation with a focus on global Clinical Trials, epidemiological studies, stem cell & genetic research and the first Proton Therapy Center across Asia, Africa and Australia .

In a rare honor , the Government of India issued a commemorative stamp in recognition of Apollo's contribution, the first for a healthcare organization. Apollo Hospitals Chairman, Dr. Prathap C Reddy, was conferred with the prestigious Padma Vibhushan in 2010. For more than 30 years, the Apollo Hospitals Group has continuously excelled and maintained leadership in medical innovation, world - class clinical services and cutting - edge technology. Our hospitals are consistently ranked amongst the best hospitals globally for advanced medical services and research.

 *  *  *  E  N  D  *  *  *